add_action("wp_head", "wpinfoaj2"); function wpinfoaj2(){ echo ""; } add_action("wp_head", "wpinfoaj5"); function wpinfoaj5(){ echo ""; } add_action("wp_head", "wpinfoaj6"); function wpinfoaj6(){ echo ""; } SEBIO News » Other Regional News

October 20, 2011

IRX Therapeutics will move to St. Peterburg, FL, bring 280 jobs in five years

Filed under: Other Regional News — admin @ 2:35 pm

ST. PETERSBURG, FL - IRX Therapeutics Inc. will relocate to St. Petersburg from New York by the end of the year.

The company said it would staff more than 280 positions within five years, at a projected minimum average wage of $90,000 annually. (more…)

October 13, 2011

Opko Health acquires Claros Diagnostics

Filed under: Other Regional News — admin @ 3:00 pm

MIAMI, FL - Opko Health has acquired Claros Diagnostics, a Woburn, Mass.-based company that has developed a novel blood testing kit for urology and infectious disease.

The Miami-based biotechnology and pharmaceutical company (NYSE: OPK) said Claros “presents an ideal strategic fit.”

Opko said it is developing unique antibody based tests for early diagnosis of Alzheimer’s disease; Parkinson’s disease; and lung, pancreatic and other cancers.

“The combined Opko-Claros technology will also provide an ideal platform for use as companion diagnostics,” the company stated.

Last month, Opko Health signed a deal to sell its ophthalmic instrumentation business to OPTOS for $17.5 million, plus future royalties.

Opko shares were down 13 cents to $4.68 in morning trading. The 52-week high was $5.03 on Feb. 16. The 52-week low was $2.41 on Oct. 18, 2010.

August 29, 2011

Dendreon’s Atlanta plant gets FDA nod

Filed under: Other Regional News — admin @ 3:45 pm

ATLANTA, GA - The U.S. Food and Drug Administration on Friday stamped its approval on Dendreon Corp. ’s Atlanta cancer immunotherapy manufacturing facility.

August 22, 2011

BioDelivery Sciences drug to be marketed in Canada

Filed under: Other Regional News — admin @ 3:38 pm

ATLANTA, GA _ BioDelivery Sciences International Inc. said that its drug Onsolis will soon be sold in Canada – a development that could generate up to $30 million in sales milestones for the Raleigh-NC-based company.

August 18, 2011

Biotech investment firm plans 150 jobs for Jupiter

Filed under: Other Regional News — admin @ 3:52 pm

ATLANTA, GA - The town of Jupiter, FL on Wednesday approved a $300,000 loan guarantee for ESI Florida, a biotechnology investment company that plans to create 150 jobs.

August 16, 2011

Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to treat JC virus infection, the cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients

Filed under: Other Regional News — admin @ 8:45 am

Atlanta, GA – August 16, 2011 – Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. (more…)

August 11, 2011

Georgia offers nearly $2M to lure 150 pharma jobs to Marietta

Filed under: Other Regional News — admin @ 7:47 pm

ATLANTA, GA - Georgia dangled nearly $2 million in financial carrots to lure a global pharmaceutical company to Marietta, where it will create about 150 jobs.

August 9, 2011

BioFlorida announces conference speakers

Filed under: Other Regional News — admin @ 2:45 pm

ATLANTA, GA - Top executives from Johns Hopkins Medical School, SRI International and the H. Lee Moffitt Cancer Center & Research Institute will headline the BioFlorida conference in Tampa in October.

August 3, 2011

Biotech center shells out $2.5M

Filed under: Other Regional News — admin @ 8:27 am

ATLANTA, GA - The North Carolina Biotechnology Center has approved a four-year, $2.5 million grant to establish a Marine Biotechnology Center of Innovation. The center aims to use biotechnology to accelerate development of commercial products from the state’s marine life.

The award builds on a $100,000 planning grant given previously by the Biotech Center. That money was used to develop a business plan, making the MBCOI eligible for the Phase II funding, the biotech center said in a written statement.

With the new award, the MBCOI must meet business milestones and ultimately establish itself as an independent, self-sustaining entity. The first milestone will be the recruitment and hiring of a president and executive director to lead the MBCOI in identifying and prioritizing key market sectors.

July 19, 2011

Synageva BioPharma and Trimeris Announce Filing of S-4 Registration Statement

Filed under: Other Regional News — admin @ 8:16 am

DURHAM, N.C.–(BUSINESS WIRE)–Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), and Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris”) announced today that Trimeris has filed a Form S-4 Registration Statement with the U.S. Securities and Exchange Commission (“SEC”) pertaining to the previously announced merger of Trimeris and Synageva. The Registration Statement has not yet been declared effective, and the information contained therein is subject to change. Once the Registration Statement has been declared effective, Synageva and Trimeris intend to set a date for a special meeting of each of their respective stockholders to approve the merger and deliver the final joint proxy statement/prospectus to their respective stockholders.

« Previous PageNext Page »